1,1,2,2-Tetra­kis(1,3-benzoxazol-2-yl)ethene

The title compound, C30H16N4O4, reveals crystallographic and mol­ecular symmetry and accordingly the asymmetric unit comprises one half-mol­ecule. The dihedral angle between the planes of the two geminal benzoxazole rings is 74.39 (5)°. The packing features weak C—H⋯N and π–π inter­actions [centroid–centroid distance = 3.652 (1) Å]

1,3-Dimesitylimidazolidinium tetra­chloridogold(III) dichloro­methane solvate

The title ionic compound, (C21H27N2)[AuCl4]·CH2Cl2, was obtained from the reaction of 1,3-dimesitylimidazolidinium chloride with t-BuOK and a solution of AuCl3 in tetra­hydro­furan. In the crystal structure, numerous weak C—H⋯Cl hydrogen bonds form double layers parallel to (100), which are further stabilized by π–π inter­actions between mesitylene rings [centroid–centroid distance = 4.308 (4) Å], resulting in the formation of a three-dimensional supra­molecular assembly

Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial

OBJECTIVE—Progressive nephropathy represents a substantial source of morbidity and mortality in type 1 diabetes. Increasing albuminuria is a strong predictor of progressive renal dysfunction and heightened cardiovascular risk. Early albuminuria probably reflects vascular endothelial dysfunction, which may be mediated in part by chronic inflammation

Assessment of socio-techno-economic factors affecting the market adoption and evolution of 5G networks: Evidence from the 5G-PPP CHARISMA project

5G networks are rapidly becoming the means to accommodate the complex demands of vertical sectors. The European project CHARISMA is aiming to develop a hierarchical, distributed-intelligence 5G architecture, offering low latency, security, and open access as features intrinsic to its design. Finding its place in such a complex landscape consisting of heterogeneous technologies and devices, requires the designers of the CHARISMA and other similar 5G architectures, as well as other related market actors to take into account the multiple technical, economic and social aspects that will affect the deployment and the rate of adoption of 5G networks by the general public. In this paper, a roadmapping activity identifying the key technological and socio-economic issues is performed, so as to help ensure a smooth transition from the legacy to future 5G networks. Based on the fuzzy Analytical Hierarchy Process (AHP) method, a survey of pairwise comparisons has been conducted within the CHARISMA project by 5G technology and deployment experts, with several critical aspects identified and prioritized. The conclusions drawn are expected to be a valuable tool for decision and policy makers as well as for stakeholders

Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema

<p>Abstract</p> <p>Background</p> <p>To assess the efficacy of the intravitreal (IVT) injection of Triamcinolone Acetonide (TA) as compared to posterior subtenon (SBT) capsule injection for the treatment of cystoid diabetic macular edema.</p> <p>Methods</p> <p>Fourteen patients with type II diabetes mellitus and on insulin treatment, presenting diffuse cystoid macular edema were recruited. Before TA injection all focal lakes were treated by laser photocoagulation. In the same patients one eye was assigned to 4 mg IVT injection of TA and the fellow eye was then treated with 40 mg SBT injection of TA. Before and one, three and six months after treatment we measured visual acuity with ETDRS chart as well as thickness of the macula with optical coherence tomography (OCT) and intraocular pressure (IOP).</p> <p>Results</p> <p>The eyes treated with an IVT injection displayed significant improvement in visual acuity, both after one (0.491 ± 0.070; p < 0.001) and three months (0.500 ± 0.089; p < 0.001) of treatment. Significant improvement was displayed also in eyes treated with an SBT injection, again after one (0.455 ± 0.069; p < 0.001) and three months (0.427 ± 0.065; p < 0.001). The difference between an IVT injection (0.809 ± 0.083) and SBT injection (0.460 ± 0.072) becomes significant six months after the treatment (p < 0.001).</p> <p>Macular thickness of the eyes treated with IVT injection was significantly reduced both after one (222.7 ± 13.4 μm; p < 0.001) and after three months (228.1 ± 10.6 μm; p < 0.001) of treatment. The eyes treated with SBT injection displayed significant improvement after one (220.1 ± 15.1 μm; p < 0.001) and after three months (231.3 ± 10.9 μm; p < 0.001). The difference between the eyes treated with IVT injection (385.2 ± 11.3 μm) and those treated with SBT injection (235.4 ± 8.7 μm) becomes significant six months after the treatment (p < 0.001).</p> <p>Intraocular pressure of the eyes treated with IVT injection significantly increased after one month (17.7 ± 1.1 mm/Hg; p < 0.020), three (18.2 ± 1.2 mm/Hg; p < 0.003) and six month (18.1 ± 1.3 mm/Hg; p < 0.007) when compared to baseline value (16.1 ± 1.402 mm/Hg). In the SBT injection eyes we didn't display a significant increase of intraocular pressure after one (16.4 ± 1.2 mm/Hg; p < 0.450), three (16.3 ± 1.1 mm/Hg; p < 0.630) and six months (16.2 ± 1.1 mm/Hg; p < 0.720) when compared to baseline value (16.2 ± 1.3 mm/Hg).</p> <p>Conclusion</p> <p>The parabulbar subtenon approach can be considered a valid alternative to the intravitreal injection.</p> <p>Trial registration</p> <p>Current Controlled Trials <b>ISRCTN67086909</b></p